Pacira (PCRX) Form 144: Insider Sale of 2,354 Shares ($64k)

Pacira BioSciences (PCRX) Form 144: The filer notifies a proposed sale of 2,354 shares of common stock acquired on 06/12/2025 upon restricted stock vesting.

Rhea-AI Filing Summary

Pacira BioSciences (PCRX) Form 144: The filer notifies a proposed sale of 2,354 shares of common stock acquired on 06/12/2025 upon restricted stock vesting. The shares are to be sold through Fidelity Brokerage Services LLC with an approximate aggregate market value of $64,005.26 and an indicated approximate sale date of 09/04/2025. The filing reports 44,932,721 shares outstanding for the issuer. No securities were reported sold in the prior three months. The filer represents they are unaware of undisclosed material adverse information.

Positive

• Disclosure of broker and planned sale date (Fidelity; 09/04/2025) supports transparency
• No sales in prior three months indicates this is an isolated, vesting-related disposition

Negative

• Insider sale could be interpreted by some market participants as ordinary stockholder liquidity, though size is small

Insights

Financial Analyst

TL;DR: Small insider sale tied to vesting; immaterial to market cap but relevant for disclosure and insider activity monitoring.

This Form 144 documents a routine disposition of 2,354 vested restricted shares with an aggregate market value of $64,005.26. Relative to the reported 44.93 million shares outstanding, the size is negligible, implying limited direct market impact. The use of a broker and the three-month lookback showing no prior sales indicate standard compliance with Rule 144 procedures. No material events or deviations are disclosed in the filing.

Corporate Governance Expert

TL;DR: Filing appears procedural and compliant; it documents an insider exercising compensation-related holdings.

The notice states the acquisition was via restricted stock vesting and the filer affirms no undisclosed material adverse information. Inclusion of broker details and a planned sale date aligns with required transparency for insider sales. There are no indications of accelerated selling, related-party transactions, or prior sales within three months, suggesting routine governance disclosure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Pacira BioSciences' (PCRX) Form 144 report?

The form reports a proposed sale of 2,354 common shares acquired on 06/12/2025 through restricted stock vesting, with aggregate market value $64,005.26.

When is the approximate sale date listed on the Form 144 for PCRX?

The approximate date of sale is listed as 09/04/2025.

Through which broker will the PCRX shares be sold?

The filing names Fidelity Brokerage Services LLC as the broker handling the sale.

How many shares outstanding does the filing report for the issuer?

The filing reports 44,932,721 shares outstanding.

Were any securities sold by the filer in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/04/2025 - 09:40 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001722140
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Pacira BioSciences, Inc.
SEC File Number	001-35060
Address of Issuer	2000 SIERRA POINT PARKWAY SUITE 900 BRISBANE CALIFORNIA 94005
Phone	650-242-8052
Name of Person for Whose Account the Securities are To Be Sold	Ceesay Abraham
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2354	64005.26	44932721	09/04/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/12/2025	Restricted Stock Vesting	Issuer			2354	06/12/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Today's sale took place in the Map Consulting LLC account in which Abraham Ceesay, Director of the company, is an authorized individual.
Date of Notice	09/04/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/03/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jennifer Ruchti, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Abraham Ceesay
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)